Takeda Pharmaceutical Company Limited has grown revenue 8.7% a year over three years and 6.8% a year over five, with earnings per share compounding at −23%. Revenue growth, 3-year annual rate: +8.7% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +6.8%, growth has picked up over the last three years. Earnings per share, 3-year rate: −23%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 9, FY2017 to FY2025, as filed.

TAKTakeda Pharmaceutical Company Limited

Healthcare

$18.73+24% 1Y

$18.73

$13.2352 weeks$19.05

Is it growing?

Watch

Growth is fading: earnings down −26% year on year and operating margin narrowing (−8.4 points).

2 to watch, 1 neutral

Revenue trend+7% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +7% a year.

Earnings trend−26% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−8.4 points operating

Trailing-twelve-month operating margin, 7.5% now against 15.9% a year earlier.

All from SEC EDGAR, as of Mar 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TAK growing?

Takeda Pharmaceutical Company Limited has grown revenue 8.7% a year over three years and 6.8% a year over five, with earnings per share compounding at −23%.

+8.7%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · steady growth, ahead of inflation · compounded from fiscal years as filed

Revenue growth, 5-year rate: +6.8%
Revenue growth, 5-year rate · +8.7% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −23%
Earnings per share, 3-year rate · revenue +8.7% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed